Novartis AG (Novartis AG) Days Inventory

: 173.97 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Novartis AG's Average Total Inventories for the three months ended in Dec. 2023 was $5,762 Mil. Novartis AG's Cost of Goods Sold for the three months ended in Dec. 2023 was $3,022 Mil. Hence, Novartis AG's Days Inventory for the three months ended in Dec. 2023 was 173.97.

The historical rank and industry rank for Novartis AG's Days Inventory or its related term are showing as below:

NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 127.91 Med: 169.68 Max: 216.9
Current: 177.66

During the past 13 years, Novartis AG's highest Days Inventory was 216.90. The lowest was 127.91. And the median was 169.68.

NVSEF's Days Inventory is ranked worse than
57.49% of 974 companies
in the Drug Manufacturers industry
Industry Median: 158.145 vs NVSEF: 177.66

Novartis AG's Days Inventory declined from Dec. 2022 (209.36) to Dec. 2023 (173.97).

Inventory Turnover measures how fast the company turns over its inventory within a year. Novartis AG's Inventory Turnover for the three months ended in Dec. 2023 was 0.52.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Novartis AG's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.49.

Novartis AG Days Inventory Historical Data

The historical data trend for Novartis AG's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

163.69

158.26

214.57

218.10

191.51

Novartis AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															209.36	174.80	169.36	202.55	173.97

Competitive Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novartis AG Days Inventory Distribution

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Days Inventory distribution charts can be found below:

* The bar in red indicates where Novartis AG's Days Inventory falls into.

Novartis AG Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Novartis AG's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (7175	+	5913)	/	2 )	/	12472	*	365
=	6544					/	12472	*	365
=	191.51

Novartis AG's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (5610	+	5913)	/	2 )	/	3022	*	365 / 4
=	5761.5					/	3022	*	365 / 4
=	173.97

Novartis AG (OTCPK:NVSEF) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Novartis AG's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	3022	/	5761.5
	=	0.52

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Novartis AG's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	5761.5	/	11776
	=	0.49

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Novartis AG Days Inventory Related Terms

Thank you for viewing the detailed overview of Novartis AG's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.